Current Report Filing (8-k)
November 16 2017 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
November 15, 2017
OncoCyte
Corporation
(Exact
name of registrant as specified in its charter)
California
|
|
1-37648
|
|
27-1041563
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(Address
of principal executive offices)
(510)
775-0515
(Registrant's
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
c
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
c
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
c
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
c
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,”
“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual
results to differ materially from the results anticipated in these forward-looking statements are contained in OncoCyte Corporation’s
Form 10 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and
other filings that OncoCyte may make with the SEC. Undue reliance should not be placed on these forward-looking statements which
speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required
by law, OncoCyte disclaims any intent or obligation to update these forward-looking statements.
References
to “OncoCyte,” “we” or “us” are references to OncoCyte Corporation
Section
1 - Registrant’s Business and Operations
Item
1.01 - Entry into a Material Definitive Agreement.
Effective
November 15, 2017, we appointed Mitchell Levine as our new Chief Financial Officer and agreed to provide him the compensation
described in Item 5.02 of this Report, which is incorporated into this Item 1.01 by reference.
Section
5 - Corporate Governance and Management
Item
5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
We
have appointed Mitchell Levine as Chief Financial Officer, effective November 15, 2017. Mr. Levine succeeds Russell Skibsted who
is the Chief Financial Officer of our former parent company BioTime, Inc. (“BioTime”) and who served as our Chief
Financial Officer as well with BioTime’s permission. We compensated BioTime for providing Mr. Skibsted’s services
under a Shared Facilities and Services Agreement. Mr. Skibsted remains BioTime’s Chief Financial Officer.
Prior
to being appointed as our Chief Financial Officer, Mr. Levine was managing partner of Kirby Cove Capital Advisors, which provides
consulting services to life sciences investment funds regarding collaboration and investment in US-based life sciences companies.
Mr. Levine was the founder and from 2002 to 2017 the managing member of Enable Capital Management, LLC, the general partner of
Enable Growth Partners, LP which provided capital to technology, life sciences, consumer products, energy and manufacturing companies.
Previously, Mr. Levine founded and managed Enable Capital, LLC and the Shemano Group, which provided capital to growth companies.
Mr.
Levine will receive an annual salary of $330,000 and a grant of options to purchase 200,000 shares of OncoCyte common stock at
an exercise price of $5.90 per share. Mr. Levine’s stock options will be subject to the terms and conditions of a stock
option agreement and our Employee Stock Option Plan. Twenty-five percent of his options will vest, and thereby become exercisable,
upon the completion of one year of employment by, and the balance will vest in 36 equal monthly installments commencing on the
first anniversary of the date of grant, based upon his continued employment by OncoCyte, and will expire if not exercised within
ten years from the date of grant.
Mr.
Levine may also receive an additional grant of options to purchase 50,000 shares of OncoCyte common stock during 2018, subject
to approval by the Board of Directors.
Mr.
Levine may be eligible for an annual bonus equal to forty percent (40%) of his base annual salary, as may be approved by the Board
of Directors in its discretion, based on his performance and achievement of goals or milestones set by the Board of Directors
or the Compensation Committee from time to time. Ms. Levine will be eligible to participate in OncoCyte’s benefit programs,
including, but not limited to retirement, pension, life, health, accident and disability insurance, equity compensation or other
similar employee benefit plans which may be adopted by OncoCyte for its employees on the same terms as similarly situated and
performing senior executives of OncoCyte.
Commencing
August 1, 2018, Mr. Levine will be entitled to severance benefits in the event that his employment is terminated by us after that
date without “cause” as will be defined in an Employment Agreement, or following a “change of control”
of OncoCyte, also as will be defined in an Employment Agreement. If we terminate Mr. Levine’s employment without “cause”
after August 1, 2018, the severance benefits will be payment of six months base salary. However, if the termination of his employment
without “cause” occurs after August 1, 2018 and within twelve months following a “change of control,”
his severance benefits will include twelve months base salary. In order to receive the severance benefits, Mr. Levine will be
required to execute a general release of all claims against OncoCyte and to return all OncoCyte property in his possession.
The
foregoing description of the terms of Mr. Levine’s employment arrangement is a summary only, does not purport to be complete.
The full terms of Mr. Levine’s employment will be contained in an employment agreement which will be filed as an exhibit
to our Annual Report on Form 10-K for the 12 months ending December 31, 2017.
Item
9.01 - Financial Statements and Exhibits
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOCYTE
CORPORATION
|
|
|
|
Date:
November 15, 2017
|
By:
|
/
s/
William Annett
|
|
|
William
Annett
|
|
|
President
and Chief Executive Officer
|
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024